BHC Logo

Bausch Health Cos Inc (BHC) Stock Forecast & Price Prediction

Live BHC Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NYSE | Healthcare | Drug Manufacturers - Specialty & Generic

$7.34

+0.08 (1.10%)

12 Month Price Forecast For BHC

$7.34
Current Price
$2.70B
Market Cap
6 Ratings
Buy 1
Hold 4
Sell 1
Wall St Analyst Ratings

Distance to BHC Price Forecasts

+63.5%
To High Target of $12.00
+29.4%
To Median Target of $9.50
-4.6%
To Low Target of $7.00

BHC Price Momentum

-1.6%
1 Week Change
-5.9%
1 Month Change
-9.7%
1 Year Change
-8.9%
Year-to-Date Change
-36.0%
From 52W High of $11.46
+85.4%
From 52W Low of $3.96

๐Ÿค” Considering Bausch Health (BHC)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 11:47 AM UTC

BHC Analyst Ratings & Price Targets

Based on our analysis of 14 Wall Street analysts, BHC has a consensus that is neutral. The median price target is $9.50, with forecasts ranging from $7.00 to $12.00. Currently, there are 1 Buy ratings, 4 Hold ratings, and 1 Sell ratings.

With BHC currently trading at $7.34, the median price forecast suggests a 29.4% upside. The most optimistic forecast comes from Douglas Miehm at RBC Capital, projecting a 63.5% upside, while Gregory Fraser at Truist Securities provides the most conservative target, suggesting a -4.6% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

BHC Analyst Consensus

1
Buy
4
Hold
1
Sell

BHC Price Target Range

Low
$7.00
Average
$9.50
High
$12.00
Current: $7.34

Latest BHC Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for BHC.

Date Firm Analyst Rating Change Price Target
Jan 30, 2025 RBC Capital Douglas Miehm Sector Perform Maintains $10.00
Nov 1, 2024 RBC Capital Douglas Miehm Sector Perform Maintains $11.00
Aug 2, 2024 Piper Sandler David Amsellem Underweight Downgrade $3.00
Aug 2, 2024 RBC Capital Douglas Miehm Sector Perform Maintains $8.50
Jul 25, 2024 Truist Securities Gregory Fraser Hold Maintains $7.00
Jul 10, 2024 Raymond James Michael Freeman Market Perform Initiates $8.00
Apr 23, 2024 RBC Capital Douglas Miehm Sector Perform Maintains $11.00
Apr 12, 2024 RBC Capital Douglas Miehm Sector Perform Reiterates $12.00
Apr 5, 2024 RBC Capital Douglas Miehm Sector Perform Maintains $12.00
Feb 23, 2024 RBC Capital Douglas Miehm Sector Perform Maintains $9.00
Sep 20, 2023 Jefferies David Steinberg Buy Upgrade $16.00
Jun 16, 2023 TD Cowen Ken Cacciatore Market Perform Downgrade $0.00
May 22, 2023 Jefferies David Steinberg Buy Maintains $9.50
May 5, 2023 RBC Capital Douglas Miehm Sector Perform Maintains $8.00
Sep 9, 2022 Piper Sandler David Amsellem Neutral Maintains $6.00
Sep 1, 2022 RBC Capital Douglas Miehm Sector Perform Maintains $8.00
Aug 10, 2022 RBC Capital Douglas Miehm Sector Perform Maintains $4.50
Aug 10, 2022 BMO Capital Gary Nachman Market Perform Maintains $8.00
Jul 29, 2022 Truist Securities Hold Downgrade $0.00
Jul 29, 2022 JP Morgan Neutral Downgrade $0.00

Stocks Similar to Bausch Health Cos Inc

The following stocks are similar to Bausch Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Bausch Health Cos Inc (BHC) Financial Data

Bausch Health Cos Inc has a market capitalization of $2.70B with a P/E ratio of -4.5x. The company generates $9.47B in trailing twelve-month revenue with a -1.9% profit margin.

Revenue growth is +12.2% quarter-over-quarter, while maintaining an operating margin of +21.7% and return on equity of +722.0%.

Valuation Metrics

Market Cap $2.70B
Enterprise Value $24.42B
P/E Ratio -4.5x
PEG Ratio 1.7x
Price/Sales 0.3x

Growth & Margins

Revenue Growth (YoY) +12.2%
Gross Margin +72.3%
Operating Margin +21.7%
Net Margin -1.9%
EPS Growth N/A

Financial Health

Cash/Price Ratio +26.6%
Current Ratio 1.2x
Debt/Equity -88.9x
ROE +722.0%
ROA +4.2%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Bausch Health Cos Inc logo

Bausch Health Cos Inc (BHC) Company Overview

About Bausch Health Cos Inc

What They Do

Diversified specialty pharmaceutical and medical device company.

Business Model

The company generates revenue through the development, manufacturing, and marketing of a wide range of pharmaceutical and medical device products across various therapeutic areas, including gastroenterology, dermatology, and ophthalmology. Its operations are segmented into five key areas, allowing it to cater to diverse markets both domestically and internationally.

Additional Information

With a strong focus on innovation and a broad portfolio of products, the company is positioned to meet the growing healthcare needs. Bausch Health Companies Inc. has a history of strategic rebranding and currently operates under its new name since July 2018, reflecting its commitment to evolving its business.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

20,270

CEO

Mr. Thomas J. Appio

Country

Canada

IPO Year

2018

Bausch Health Cos Inc (BHC) Latest News & Analysis

BHC stock latest news image
Quick Summary

Bausch Health Companies Inc. will release Q4 and full year 2024 financial results on February 19, 2025, after market close, followed by a conference call at 5:00 p.m. ET.

Why It Matters

The upcoming earnings release and conference call could impact Bausch Health's stock price, influencing investor sentiment and trading strategies based on performance insights.

Source: Accesswire
Market Sentiment: Neutral
BHC stock latest news image
Quick Summary

Bausch + Lomb (NYSE/TSX: BLCO) will release its Q4 and full-year 2024 financial results on February 19, 2025, followed by a conference call at 8 a.m. ET. Investor materials will be available online.

Why It Matters

Bausch + Lomb's upcoming financial results and business update could influence stock performance and investor sentiment, highlighting insights into company growth and market position.

Source: Business Wire
Market Sentiment: Neutral
BHC stock latest news image
Quick Summary

Bausch Health's XIFAXANยฎ has been selected for CMS's drug price negotiations under the Inflation Reduction Act, with initial price applicability set for 2027.

Why It Matters

Bausch Health's XIFAXANยฎ facing CMS negotiation could impact pricing and revenue post-2027, affecting future earnings and investor sentiment in the pharmaceutical sector.

Source: Accesswire
Market Sentiment: Neutral
BHC stock latest news image
Quick Summary

Analysts' price targets for Bausch (BHC) suggest a 25.5% upside, supported by consensus on raised earnings estimates, indicating potential stock growth.

Why It Matters

Analysts' price targets suggest a 25.5% upside for Bausch (BHC), indicating potential growth, while consensus on earnings estimates signals strong confidence in future performance.

Source: Zacks Investment Research
Market Sentiment: Positive
BHC stock latest news image
Quick Summary

Bausch and Lomb CEO Brent Saunders discussed portfolio changes and growth prospects for the company in a recent interview on 'Money Movers.'

Why It Matters

Brent Saundersโ€™ insights on portfolio changes and growth prospects can signal Bausch and Lomb's future performance, influencing investor confidence and stock valuation.

Source: CNBC Television
Market Sentiment: Positive
BHC stock latest news image
Quick Summary

Bausch and Lomb CEO Brent Saunders highlights the negative effects of excessive screen time on vision, indicating a potential market opportunity for eye care products.

Why It Matters

Increased screen time concerns may boost demand for eye care products, positively impacting Bausch and Lomb's sales and growth prospects.

Source: CNBC Television
Market Sentiment: Negative

Frequently Asked Questions About BHC Stock

What is Bausch Health Cos Inc's (BHC) stock forecast for 2025?

Based on our analysis of 14 Wall Street analysts, Bausch Health Cos Inc (BHC) has a median price target of $9.50. The highest price target is $12.00 and the lowest is $7.00.

Is BHC stock a good investment in 2025?

According to current analyst ratings, BHC has 1 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $7.34. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for BHC stock?

Wall Street analysts predict BHC stock could reach $9.50 in the next 12 months. This represents a 29.4% increase from the current price of $7.34. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Bausch Health Cos Inc's business model?

The company generates revenue through the development, manufacturing, and marketing of a wide range of pharmaceutical and medical device products across various therapeutic areas, including gastroenterology, dermatology, and ophthalmology. Its operations are segmented into five key areas, allowing it to cater to diverse markets both domestically and internationally.

What is the highest forecasted price for BHC Bausch Health Cos Inc?

The highest price target for BHC is $12.00 from Douglas Miehm at RBC Capital, which represents a 63.5% increase from the current price of $7.34.

What is the lowest forecasted price for BHC Bausch Health Cos Inc?

The lowest price target for BHC is $7.00 from Gregory Fraser at Truist Securities, which represents a -4.6% decrease from the current price of $7.34.

What is the overall BHC consensus from analysts for Bausch Health Cos Inc?

The overall analyst consensus for BHC is neutral. Out of 14 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $9.50.

How accurate are BHC stock price projections?

Stock price projections, including those for Bausch Health Cos Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.